November 26, 2024
OncoHost Highlights Advances in Proteomic Research with Abstracts Presented at ISLB 2024 6th Annual Congress of Liquid Biopsy
BINYAMINA, Israel and CARY, NC – November 26,2024 - OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that its research featured in three abstracts selected for presentation at the ISLB 2024 6th Annual Congress of Liquid Biopsy. The research presented included three poster presentations, each showcasing the potential of plasma proteomics in advancing personalized treatment strategies for lung cancer patients.
Poster Presentation 1
Title: A Plasma Proteomics Composite Biomarker: Predicting Immunotherapy Outcomes in NSCLC and tailoring treatment strategy
Presenter: Michal Harel, PhD, Director of Science and Innovation, OncoHost
Immune checkpoint inhibitors (ICIs)have shown considerable efficacy in treating patients with advanced non-small cell lung cancer (NSCLC), yet overcoming drug resistance remains a critical challenge. OncoHost developed PROphetNSCLC™, an advanced decision support tool that leverages the analysis of 388 baseline plasma proteins, collectively known as ‘resistance-associated proteins’ (RAPs). This research centers on the bioinformatics and clinical evaluation of RAPs to investigate the mechanisms driving resistance to ICIs. Dr. Harel’s presentation highlighted how this study deepens the understanding of ICI resistance biology in NSCLC and emphasized the potential of RAP profiling to guide personalized treatment strategies.
“By profiling the plasma proteome ofnon-small cell lung cancer patients, we have uncovered keyresistance-associated proteins that not only reveal the underlying biology of ICIresistance, but also provide a roadmap for personalized treatment strategies,”said Dr. Harel. “These insights pave the way for developing personalizedtreatment plans by pinpointing specific resistance mechanisms. Our studyunderscores the clinical potential of RAP profiling to refine therapies and enhanceclinical outcomes for patients who are not responding to standard treatments.”
Poster Presentation 2
Title: Economic and Clinical Impact of Integrating the PROphetNSCLC™ Plasma Proteomic Test in mNSCLC Treatment
Presenter: Michal Harel, PhD, Director of Science and Innovation, OncoHost
OncoHost’s PROphetNSCLC™ test offers a promising approach to improve treatment management for metastatic non-small cell lung cancer (mNSCLC) by guiding optimal first-line therapeutic choices beyond PD-L1 tumor proportion score (TPS) recommendations. This health-economic simulation using real-world data evaluated the impact of integrating the test into treatment strategies in the US. Findings showed potential cost savings and improved patient outcomes, estimating that within a population of 2,000,000 covered lives, 299 mNSCLC patients could benefit from the PROphetNSCLC™ test, demonstrating its value in reducing treatment costs and enhancing overall survival (OS).
Poster Presentation 3
Title: A Randomized Trial of Immune Checkpoint Inhibitor Plasma Proteomic Biomarker and Chemotherapy Risk Model in Advanced Non-Small Cell Lung Cancer
Presenter: Surbhi Singhal, MD, Assistant Professor of Medicine, Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center
This study explores the integration of PROphet®, OncoHost’s novel plasma proteomic biomarker, with the Cancer and Aging Research GroupChemotherapy Toxicity Tool (CARG-TT) to improve treatment decision-making foradvanced NSCLC. This combined approach seeks to better predict the benefit ofimmune checkpoint inhibitors (ICIs), as well as reduce chemotherapy-relatedtoxicities. The study will enroll 32 patients to compare outcomes of using thisintegrated model versus standard biomarker testing, focusing on its influenceon treatment choices, clinician confidence, and secondary outcomes like12-month progression-free survival and adverse events.
“This clinical trial allows us to establish feasibility of combining biomarkers and clinical risk models to inform treatment selection,” said Dr. Singhal. “By opening the trial at severalcommunity oncology practice sites, in addition to an academic site, we can determine how PROphet® is used by a diversity of oncologists.”
All posters can be found on OncoHost’s website here.
###
About OncoHost
OncoHost is a technology company headquartered in Binyamina, Israel, and Cary, North Carolina, transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphetNSCLC™ test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.
For more information, visit www.oncohost.com, or follow OncoHost on LinkedIn, Twitter, Facebook and YouTube.
